Sensitivity of personalized circulating tumor DNA assay in advanced cutaneous squamous cell carcinoma

J Am Acad Dermatol. 2024 Feb;90(2):427-429. doi: 10.1016/j.jaad.2023.10.011. Epub 2023 Oct 14.

¹ Georgetown University School of Medicine, Washington, District of Columbia; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts.
² Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts; Department of Dermatology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
³ Harvard Medical School, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁴ Harvard Medical School, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Electronic address: Ann_Silk@dfci.harvard.edu.

No abstract available

Keywords: circulating tumor DNA; clinical research; cutaneous oncology; medical dermatology; squamous cell carcinoma; tumor biomarkers.

MeSH terms